Select Your Region
Global
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
- Eye Disorder
- Neovascular Age-related Macular Degeneration
- Retinal Vein Occlusion
- Diabetic Macular Edema
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Recruiting
This trial runs in
Cities
- shang-hai-shi
- wu-han-shi
Trial Identifier:
NCT06439576 ML45401
Trial Summary
The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China. It is a primary data collection, non-interventional, prospective and retrospective, multi-center study designed to collect real-world, long-term data to gain clinical evidence on faricimab, by observing cohorts of patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) who are receiving treatment with faricimab.
Hoffmann-La Roche
Sponsor
N/A
Phase
NCT06439576, ML45401
Trial Identifier
Faricimab
Treatments
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Condition
Official Title
China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Have signed the informed consent
- Female and male Chinese patients, who had been diagnosed with nAMD, DME, or RVO by CFP, OCT, FFA, ICGA, or OCTA
- ≥50 years old for patients with nAMD, ≥18 years old both for patients with DME and RVO, at the time of signing informed consent (or the first administration of faricimab, whichever occurs first)
- Patients for whom the decision to receive treatment with faricimab is made prior to and independent from study participation
- Patients have received at least one faricimab treatment (the first dose) in the study eye
Exclusion Criteria
- Patients not receiving treatment for nAMD/DME/RVO with faricimab according to the standard of care and in line with the current summary of product characteristics (SPC) / labeling in China
- Active ocular inflammation or suspected / active ocular infection in either eye
- Received any other anti-VEGF treatment after faricimab
- Received any steroid treatment within 6 months (180 days) before the first faricimab treatment in the study eye
- Any participation in any other clinical trials currently
- Patients could not provide the clinical data (visual acuity and OCT images) within 2 weeks (14 days) before receiving the initial faricimab injection
For the latest version of this information please go to www.forpatients.roche.com